Sarepta Therapeutics, Inc.
Company Stats
- Market Cap
- $1.9B
- as of Sep 30, 2026
- Shares Outstanding
- 105.6M
- Free Float
- 79.7%
Income Statement
- Revenue
- $2.2B
- Operating Income
- -$699.8M
- Net Income
- -$713.4M
- EBITDA
- -$655.3M
- Revenue Growth, 3Y
- 33.1%
- FCF Margin, 3Y Avg
- -26.1%
- FCF Margin, Worst Year
- -46.4%
Cash Flow
- Free Cash Flow
- -$307.5M
- FCF Yield
- -16.0%
- Owner FCF Yield
- -22.4%
Balance Sheet
- Cash & Equivalents
- $801.3M
Returns & Capital
- Share Repurchases
- $25.0M
- Buyback Yield, 3Y Avg
- 0.4%
- SBC, 3Y Avg
- $163.4M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $2.2B | -$307.5M | -14.0% |
| FY2024 | $1.9B | -$342.7M | -18.0% |
| FY2023 | $1.2B | -$577.1M | -46.4% |
| FY2022 | $933.0M | -$356.2M | -38.2% |
| FY2021 | $701.9M | -$481.7M | -68.6% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 8, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back